Clinical Trial Update: Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 non-randomized safety study evaluating the combination of Bortezomib and Rituximab in relapsed/refractory indo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | Conditions: Lymphoma, Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED